CAM
MNTA

Cormorant Asset Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Cormorant Asset Management’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-27,700
Closed -$490K – 52
2013
Q4 		$490K Buy
+27,700
New +$465K 0.14% 33

Other funds holding MNTA

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cormorant Asset Management's MNTA Position: Q1 2014 in Review

Cormorant Asset Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2014, closing a stake of 27,700 shares — an estimated $490K sold.

Cormorant Asset Management first reported a position in MNTA in Q4 2013 and held it in 1 quarter. The position peaked at $490K in Q4 2013. 158 funds tracked by Wall St. Rank hold MNTA as of Q1 2014.

  • Cormorant Asset Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Cormorant Asset Management sold 27,700 Momenta Pharmaceuticals, Inc. shares in Q1 2014, an estimated $490K.
  • Cormorant Asset Management first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2013 and held it in 1 quarter.
  • Cormorant Asset Management's Momenta Pharmaceuticals, Inc. position peaked at $490K in Q4 2013.
  • 158 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2014.

Based on Cormorant Asset Management's 13F filing for Q1 2014, filed 15 May 2014.